For as long as anyone with Huntington's disease has been alive, there has been no treatment proven to slow it.
Huntington's is inherited. It is fatal. It is caused by a single genetic mutation — a glitch in the huntingtin gene — that causes nerve cells in the brain to progressively break down. Patients develop uncontrolled movements, cognitive decline, and psychiatric symptoms that worsen, without pause, until death. Around 8,000 people in the UK live with Huntington's disease. An estimated 30,000 Americans. And because it is genetic, every child of an affected parent faces a 50% chance of inheriting the condition.
For all of them, there has been nothing to slow the clock.
Until now.
A landmark clinical study of AMT-130 — a gene therapy developed by Dutch biotech uniQure — has shown that patients receiving a higher dose of the treatment experienced 75% less disease progression after three years, alongside a measurably slower decline in movement and thinking. The study was supported by the National Institute for Health and Care Research (NIHR) in the UK, and published March 5, 2026.
AMT-130 is the first gene therapy ever to be tested in humans with Huntington's disease. It works by delivering a micro-RNA directly into the brain — via a single intrastriatal injection into the striatum, the region most affected by the disease — that silences the mutant huntingtin protein responsible for the neurological damage. The goal is not to restore what is lost, but to stop the loss continuing.
The NIHR provided crucial infrastructure for the study: an NIHR Biomedical Research Centre and Clinical Research Facility offered expert scientific advice, specialist NHS facilities, and skilled research staff. A long-term observational study provided a rigorous comparison group of patients not receiving the treatment, ensuring the results were robust.
For patients and families, this represents long-awaited hope — the first signal that the progression of this devastating disease can be interrupted, not just managed.
The science is early. Phase II trials are underway. Larger confirmatory data will be needed. But the signal is real, and it is significant.
For everyone who has watched a family member change before their eyes, unable to stop it — for every person who has held a positive genetic test and wondered how much time they had — today is different from yesterday.
The clock can be slowed. The evidence says so.
That matters enormously. 💚